Trial Profile
Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology as a Sole Metastatic Site, a Pilot Study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 07 Jul 2020 Planned End Date changed from 1 May 2021 to 1 May 2023.
- 07 Jul 2020 Planned primary completion date changed from 1 May 2020 to 1 May 2022.
- 18 Oct 2018 New trial record